Drug Information
| Drug General Information | |||||
|---|---|---|---|---|---|
| Drug ID |
D0BG3B
|
||||
| Former ID |
DIB008930
|
||||
| Drug Name |
VX-135
|
||||
| Indication | HCV infection [ICD9: 070.4, 070.5, 070.70; ICD10:B17.1, B18.2] | Phase 2 | [1] | ||
| Company |
Vertex pharmaceuticals
|
||||
| Target and Pathway | |||||
| Target(s) | Hepatitis C virus NS5B polymerase | Target Info | Inhibitor | [2] | |
| References | |||||
| REF 1 | ClinicalTrials.gov (NCT01726946) A Phase 2 Study to Evaluate the Safety and Efficacy of VX-135 With Ribavirin in Treatment-Naive Subjects With Chronic Hepatitis C. U.S. National Institutes of Health. | ||||
| REF 2 | All-oral HCV therapies near approval. Nat Rev Drug Discov. 2013 Jun;12(6):409-11. doi: 10.1038/nrd4036. | ||||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.